

RECEIVED

MAY 10 2002

USPTO Form 1449 (modified) U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE
CITATION

Page 1 of 11

Attorney Docket No.
161765.00467Serial No.
TECH CENTER 1600/2000

Applicant(s): Len F. LEE et al.

Filing Date: February 8, 2002

Examiner: TBA

Group: 1626

U.S. PATENT DOCUMENTS

Examiner Initial	Doc Tab No.	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
De	1	3,262,850	07/26/66	Glynn			
	2	3,287,370	11/22/66	Mohrbacher			
	3	3,389,144	06/18/68	Mohrbacher			
	4	3,520,891	07/21/70	Mohrbacher			
	5	3,674,836	07/04/72	Creger			
	6	3,692,895	09/19/72	Nelson			
	7	3,714,190	01/30/73	Boissier			
	8	3,781,328	12/25/73	Witte			
	9	3,948,973	04/06/76	Phillips			
	10	3,962,261	06/08/76	Zinnes			
	11	3,972,878	08/03/76	Schirmann			
	12	3,983,140	09/28/76	Endo			
	13	4,002,750	01/11/77	Ambrogi			
	14	4,058,552	11/15/77	Mieville			
	15	4,185,109	01/22/80	Rosen			
	16	4,231,938	11/04/80	Monaghan			
	17	4,251,526	02/17/81	McCall			
	18	4,346,227	08/24/82	Terahara			
	19	4,444,784	04/24/84	Hoffman			
	20	4,559,332	12/17/85	Grob			
	21	5,075,293	12/24/91	Reifschneider			
	22	5,153,184	10/06/92	Reifschneider			
	23	5,158,943	10/27/92	Sohda			
	24	5,244,887	09/14/93	Straub			
	25	5,260,316	11/09/93	Van Duzer			
	26	5,334,600	08/02/94	Van Duzer			
	27	5,350,761	09/27/94	Van Duzer			
	28	5,354,772	10/11/94	Kathawala			
	29	5,430,116	07/04/95	Kramer			
	30	5,502,045	03/26/96	Miettinen			
	31	5,512,558	04/30/96	Enhnen			
	32	5,519,001	05/21/96	Rampratap			
	33	5,602,152	02/11/97	Berthelon			
	34	5,610,151	03/11/97	Glombik			
	35	5,663,165	09/02/97	Brieddy			
	36	5,703,188	12/30/97	Mandeville			
	37	5,705,524	01/06/98	McGee			
	38	5,723,458	03/03/98	Brieddy			
	39	5,767,115	06/16/98	Rosenblum			
✓	40	5,929,062	07/27/99	Haines			


RECEIVED

MAY 10 2002

Serial No.

10/068-297
TECH CENTER 1600/2900USPTO Form 1449 (modified) U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE
CITATION

Page 2 of 11

Attorney Docket No.
161765.00467

Applicant(s): Len F. LEE et al.

Filing Date: February 8, 2002

Examiner: TBA

Group: 1626

	41		11/30/99	Lee			
	42	6,020,330	02/01/00	Enhssen			
	43	6,034,118	03/07/00	Bischofberger			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
DL	44	AU-A-30209/92	12/17/92	Australia				x
	45	AU-A-61946/94	06/05/94	Australia				x
	46	AU-A-61948/94	06/05/94	Australia				x
	47	AU-A-61949/94	06/05/94	Australia				x
	48	2,025,294	03/15/91	Canada				
	49	2,078,588	03/22/93	Canada				
	50	2,085,782	06/21/93	Canada				
	51	2,085,830	06/21/93	Canada				
	52	0 067 086	10/05/82	Europe				
	53	0 129 748	02/01/85	Europe				
	54	0 250 265	06/19/87	Europe				
	55	0 338 331	06/04/89	Europe				
	56	0 379 161	01/17/90	Europe				
	57	0 508 425 A1	09/04/92	Europe				
	58	0 526 402 A1	02/03/93	Europe				
	59	0 531 901 A2	02/09/92	Europe				
	60	0 549 967 A1	12/17/92	Europe				
	61	0 559 064 A2	02/24/93	Europe				
	62	0 563 731 A1	03/22/93	Europe				
	63	0 568 898 A1	04/27/93	Europe				
	64	0 796 846 A1	07/03/97	Europe				x
	65	0 801 060 A1	15/10/97	Europe				
	66	0 818 197 A1	06/25/97	Europe				x
	67	0 818 448 A1	06/24/97	Europe				x
	68	2 661 676-A1	02/05/90	France				
	69	196 27 430 A1	08/07/96	Germany				x
	70	1211258	02/01/68	Germany				
	71	10-287662	10/27/98	Japan				x
	72	89/01477	02/23/89	PCT			Abst	
	73	91/08205	06/13/91	PCT			Abst	
	74	92/17467	10/15/92	PCT			Abst	
	75	92/18115	10/29/92	PCT			Abst	
	76	92/18462	10/29/92	PCT			Abst	
	77	93/16055	08/19/93	PCT			Abst	
	78	93/21146	10/28/93	PCT			Abst	
V	79	94/18183	08/18/94	PCT			Abst	

RECEIVED

MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office			U.S. Department of Commerce			Attorney Docket No. 161765.00467		Serial No. 161765.00467			
INFORMATION DISCLOSURE CITATION Page 3 of 11						Applicant(s): Len F. LEE et al.					
						Filing Date: February 8, 2002				Examiner: TBA	
										Group: 1626	
	80	94/00184	08/18/94	PCT			Abst				
	81	94/24087	10/27/94	PCT			Abst				
	82	95/21843	08/17/95	PCT			Abst				
	83	96/05188	02/22/96	PCT			Abst				
	84	96/08484	03/21/96	PCT			Abst				
	85	96/16051	05/30/96	PCT			Abst				
	86	96/40255	12/19/96	PCT			Abst				
	87	97/03953	02/02/97	PCT			Abst				
	88	97/33882	09/18/97	PCT			Abst				
	89	97/49387	12/31/97	PCT			Abst				
	90	97/49736	12/31/97	PCT			Abst				
	91	98/02432	01/22/98	PCT			Abst				
	92	98/06405	02/19/98	PCT			Abst				
	93	98/23593	06/04/98	PCT			Abst				
	94	98/35937	08/20/98	PCT			Abst				
	95	98/38182	09/03/98	PCT			Abst				
	96	98/39299	09/11/98	PCT			Abst				
	97	98/40375	09/17/98	PCT			Abst				
	98	98/56757	12/17/98	PCT			Abst				
	99	99/11259	03/11/99	PCT							
	100	99/11260	03/11/99	PCT							
	101	99/11263	03/11/99	PCT							
	102	99/14174	03/25/99	PCT			Abst				
	103	99/14204	03/25/99	PCT							
	104	99/14215	03/25/99	PCT			Abst				
	105	99/32478	07/01/99	PCT							
	106	99/35135	07/15/99	PCT							
	107	99/64409	12/16/99	PCT			Abst				
	108	00/35889	06/22/00	PCT			Abst				
	109	2 305 665	04/16/97	United Kingdom							
	110	2 329 334	03/24/99	United Kingdom							
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)											
	111	A. Barrett et al., "Total Synthesis and Stereochemical Assignment of the Quinquecyclopropane-Containing Cholesteryl Ester Transfer Protein Inhibitor U-106305", J. Am Chem. Soc., 1996, 118, pgs. 7863-7864									
	112	P. Barter et al. "High Density Lipoproteins and Coronary Heart Disease", Atherosclerosis, 121 1996, pgs. 1-12.									
	113	A. Beckwith et al., "Iododediazoniation of Arenediazonium Salts Accompanied by Aryl Radical Ring Closure" J. Org. Chem. 1987, Vol. 52, pgs. 1922-1930									
	114	D. Bilheimer et al., "Mevinolin and Colestipol Stimulate Receptor-Mediated Clearance of Low Density Lipoprotein From Plasma In Familial Hypercholesterolemia Heterozygotes", Proc. Natl. Acad. Sci. USA, Vol. 80, July 1983, pgs. 4124-4128									

RECEIVED

MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 161765.00467		TECH CENTER 1600/2990 10/068,297	
INFORMATION DISCLOSURE CITATION				Applicant(s): Len F. LEE et al.			
Page 4 of 11				Filing Date: February 8, 2002		Examiner: TBA Group: 1626	
DCE	115	C. Bisgaier et al., "Cholesteryl Ester Transfer Protein Inhibition By PD 140195, Lipids, Vol. 29, No. 12, 1994, pgs. 811-818					
	116	D. Blankenhorn et al., "Beneficial Effects of Combined Colestipol-Niacin Therapy On Coronary Atherosclerosis and Coronary Venous Bypass Grafts", JAMA, June 19, 1987, Vol. 257, No. 23, pgs. 3233-3240					
	117	D. Blankenhorn et al., "Beneficial Effects of Colestipol-Niacin Therapy on the Common Carotid Artery" Circulation Vol. 88, 1 July 1993, pgs. 20-28					
	118	P. Bonin et al., "A Peptide Inhibitor Of Cholesteryl Ester Transfer Protein Identified By Screening a Bacteriophage Display Library", Journal of Peptide Research, 51, 1998, pgs. 216-225					
	119	G. Brown, et al., "Regression of Coronary Artery Disease As A Result of Intensive Lipid-Lowering Therapy in Men With High Levels Of Apolipoprotein B", The New England Journal of Medicine, Volume 323, November 8, 1990, Number 19, pgs. 1289-1339.					
	120	M. Brown et al., "Induction of 3-hydroxy-3Methylglutaryl Coenzyme A Reductase Activity in Human Fibroblasts Incubated with Compactin (ML-236B), A Competitive Inhibitor of the Reductase, The Journal of Biological Chemistry, Vol. 253, No. 4, February 22, 1978, pgs. 1121-1128					
	121	S. Busch et al., "Cholesteryl Ester Analogs Inhibit Cholesteryl Ester But Not Triglyceride Transfer Catalyzed By The Plasma Cholesteryl Ester-Triglyceride Transfer Protein", Lipids, Vol. 25, No. 4 (1990), pgs. 216-220					
	122	C. Camoutsis et al., "N-Substituted 4, 5-Dihydro-1, 2-Benzothiazepin-3-One 1, 1-Dioxide", J. Heterocyclic Chem. 17, pgs. 1135-1136 (1980)					
	123	L. Cashin-Hemphill et al., "Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis A 4-Year Follow-up", JAMA, December 19, 1990, Vol. 264, No. 23, pgs. 3013-3017					
	124	P. Catsoulacos et al., "Synthesis of Some N-Substituted 4,5-Dihydro-7,8-dimethoxybenzothiazepin-3-one 1,1-Dioxides", J. Heterocyclic Chem., Vol. 13 (1976), pgs. 1309-1314					
	125	P. Catsoulacos et al., "Thiazo Compounds. Derivatives of 4, 5-Dihydro-7, 8-Dimethoxybenzothiazepin-3 one 1, 1-Dioxides", Journal of Chemical and Engineering Data, Vol. 22, No. 3, 1977, pgs. 353-354					
	126	K. Cho et al, "A Peptide From Hog Plasma that Inhibits Human Cholesteryl Ester Transfer Protein", Biochimica et Biophysica Acta, 1391, 1998, pgs. 133-144					
	127	D. Connolly et al., "Inactivation of Cholesteryl Ester Transfer Protein by Cysteine Modification", Biochemical and Biophysical Research Communications 223, pgs. 42-47, 1996					
	128	S. Coval et al., "Wiedendiol-A and-B, Cholesteryl Ester Transfer Protein Inhibitors From The Marine Sponge Xestospongia Wiedenmayeri", Bioorganic & Medicinal Chemistry Letter, Vol. 5, No. 6, pgs. 605-610, 1995					
	129	J. Davignon et al., "Apolipoprotein E and Atherosclerosis: Quest for an APO E Receptor Defect Leads to the Discovery of Pseudo Type III Dyslipoproteinemia in a Family", Atherosclerosis IX, pgs. 199-203, 1995.					
130	J. Davignon et al., "Comparative Efficacy and Safety of Pravastatin, Nicotinic Acid and The Two Combined in Patients with Hypercholesterolemia", The American Journal of Cardiology, February 15, 1994, pgs. 339-345						


RECEIVED

MAY 10 2007

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 161765.00467		Serial No. 1006809	
INFORMATION DISCLOSURE CITATION				TECH CENTER 1000/2900			
Page 5 of 11				Applicant(s): Len F. LEE et al.			
				Filing Date: February 8, 2002		Examiner: TBA	
						Group: 1626	
131	DA	J. Emmerich et al., "Combination Drug Therapy for Familial Combined Hyperlipidemia", Annals of Internal Medicine, July 1, 1988, pgs. 25-32					
132		J. Emmerich et al., "Efficacy and Safety of Simvastatin (Alone or in Association with Cholestyramine) A 1 yr. Study in 66 Patients with Type II Hyperlipoproteinaemia", European Heart Journal (1990), 11, pgs. 149-155					
133		D. Erkelens, "Combination Drug Therapy with HMG Co A Reductase Inhibitors and Bile Acid Sequestrants for Hypercholesterolemia", Cardiology, 1990, 77, (suppl 4), pgs. 33-38					
134		H. Ginsberg, "Update on the Treatment of Hypercholesterolemia, with a Focus on HMG-CoA Reductase Inhibitors and Combination Regimens", Clinical Cardiology 18, pgs. 307-315, (1995)					
135		C. Glueck et al., "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemias" The American Journal of Cardiology, July 1, 1992, Vol. 70, No. 1, pgs. 1-9					
136		S. Grundy et al., "Influence of Combined Therapy with Mevinolin and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial Hypercholesterolemia", Annals of Internal Medicine, 1985, 103: pgs. 339-343					
137		H. Gylling et al., "Effects Of Inhibiting Cholesterol Absorption And Synthesis On Cholesterol And Lipoprotein Metabolism In Hypercholesterolemic Non-Insulin-Dependent Diabetic Men", Journal of Lipid Research, Volume 37, 1996, pgs. 1776-1785					
138		E. Haber, "Molecular Cardiovascular Medicine" Scientific American, pgs. 35-40					
139		V. Hegde et al., "A Depsipeptide Fungal Metabolite Inhibitor Of Cholesteryl Ester Transfer Protein", Bioorganic & Medicinal Chemistry Letters 8, 1998, pgs. 1277-1280					
140		L. Hellberg et al., "5a-Hydroxy-3a-Cholestanecarboxylic" The New Journal for Organic Synthesis, Vol. 15, Number 1-2, February-April 1983, pgs. 154-156					
141		J. Heubi et al., "Primary Bile Acid Malabsorption: Defective In Vitro Ileal Active Bile Acid Transport", Gastroenterology 1982, 83: pgs. 804-11					
142		N. Hoogerbrugge et al., "The Additional Effects of Acipimox To Simvastatin In The Treatment of Combined Hyperlipidaemia", Journal of Internal Medicine, 1997, 241: pgs. 151-155					
143		N. Hoogerbrugge et al., "The Efficacy and Safety of Pravastatin, Compared To And In Combination With Bile Acid Binding Resins, In Familial Hypercholesterolaemia", Journal of Internal Medicine 1990, 228; pgs. 261-266					
144		A. Hutchesson et al., "Dual Bezafibrate-Simvastatin Therapy For Combined Hyperlipidaemia", Journal of Clinical Pharmacy and Therapeutics 1994, 19, pgs. 387-389					
145		T. Ichihashi, "Mechanism of Hypocholesterolemic Action of S-8921 in Rats: S-8921 Inhibits Ileal Bile Acid Absorption", The Journal Of Pharmacology And Experimental Therapeutics, Vol. 284, No. 1, pgs. 43-50, 1994					
146		D. Illingworth, et al., "Influence of Lovastatin plus Gemfibrozil on Plasma Lipids and Lipoproteins in Patients With Heterozygous Familial Hypercholesterolemia", Circulation Vol. 79, Number 3, March 1989, 590-596					
147		D. Illingworth, "Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia", Annals of Internal Medicine, 1984, 101, pgs. 598-604					
148		International Search Report mailed May 23, 2000 based on PCT/US 99/27942					
149		International Search Report mailed May 23, 2000 based on PCT/US 99/27943					
150		International Search Report mailed May 23, 2000 based on PCT/US 99/27944					
151		International Search Report mailed May 23, 2000 based on PCT/US 99/27945					
152	✓	International Search Report mailed May 18, 2000 based on PCT/US 99/27947					



RECEIVED
MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 161765.00467		TECH CENTER 1600/2990 10/068,297	
INFORMATION DISCLOSURE CITATION				Applicant(s): Len F. LEE et al.			
Page 6 of 11				Filing Date: February 8, 2002		Examiner: TBA Group: 1626	
							
DCE		153	International Search Report mailed May 15, 2000 based on PCT/US 99/27948				
		154	International Search Report mailed May 17, 2000 based on PCT/US 99/27949				
		155	J. Kane, et al., "Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens", JAMA, December 19, 1990, Chapter 26, Vol. 264, No. 23, pgs. 3007-3012				
		156	A. Katritzky et al., "Preparation Of 6-7- And 8-Membered Sultams By Friedel-Crafts Cyclization Of w-Phenylalkanesulfamoyl Chlorides", Organic Preparations and Procedures Int., 24 (4), pgs. 463-467 (1992)				
		157	T. Kazumi et al., "Effects of Niceritrol On Elevated Serum Lipoprotein LP (A) Levels in Diabetic Patients With Or Without Overt Proteinuria", Current Therapeutic Research, Vol. 55, No. 5, May 1994, pgs. 546-551				
		158	W. Kramer, et al., "Intestinal Bile Acid Absorption", The Journal of Biological Chemistry". Vol. 268, No. 24 Issue of August 25, pgs. 18035-18046, 1993				
		159	Kuo, M.S. et al., "Discovery, Isolation, Structure Elucidation, and Biosynthesis of U-106305, a Cholesteryl Ester Transfer Protein Inhibitor from UC 11136", J. Am. Chem. Soc. 117, pp. 10629-10634 (1995)				
		160	Kvis, K. et al. , "Benzocycloheptenes and Heterocyclic Analogues as Potential Drugs. VII, 4-Phenyl-,3,4,5-Tetrahydro-1-Benzothiepins and Some Related Compounds", Chem. Commun./Vo.37/(1973) pgs. 3808-3816				
		161	Lee, J.C. et al., "A Cholesteryl Ester Transfer Protein Inhibitor from an Insect-associated Fungus", The Journal of Antibiotics 49(7), pp. 693-696, 1973				
		162	A.M. Lees et al., "Therapy of Hypercholesterolemia With Mevinolin And Other Lipid-Lowering Drugs", Arteriosclerosis 6, 1986, pg. 544a				
		163	T. Leren et al., "Effects of Lovastatin Alone and In Combination with Cholestyramine on Serum Lipids and Apolipoproteins in Heterozygotes for Familial Hypercholesterolemia", International Journal for Research and Investigation on Atherosclerosis and Related Diseases, 73, (1988), pgs. 135-141				
		164	M. Lewis, et al., "Effects Of 2164U90 on Ileal Bile Acid Absorption and Serum Cholesterol in Rats and Mice, Journal of Lipid Research, Vol. 36, 1995, pgs. 1098-1105				
		165	R. Lewis, Hawley's Condensed Chemical Dictionary, pg. 1238, 1990.				
		166	W. Ling et al., "Minireview Dietary Phytosterols A Review of Metabolism, Benefits and Side Effects", Life Sciences, Vol. 57, No. 3, 1995, pgs. 195-206				
		167	H. Mabuchi et al., "Reduction of Serum Cholesterol In Heterozygous Patients with Familial Hypercholesterolemia", The New England Journal of Medicine, Vol. 308, March 17, 1983, pgs. 609-613				
		168	M. Malloy et al., "Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia", Annals of Internal Medicine 1987; 107: pgs. 616-623				
		169	W. Mandeville et al., "Bile Acid Sequestrants: Their Use In Combination With Other Lipid-Lowering Agents, Idrugs 1999 Vol. 2., No. 3, pgs. 237-242				
		170	G. Marais et al., "Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy", Annals of Internal Medicine, February 1, 1990, Volume 112, Number 3, pgs. 228-230				
✓		171	P. McCarthy, "New Approaches to Atherosclerosis: An Overview", Medicinal Research Reviews, Vol. 13, No. 2, 1993, pgs. 139-159				


RECEIVED

MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 161765.00467	Serial No. TECH CENTER 1600/2900
INFORMATION DISCLOSURE CITATION		Applicant(s): Len F. LEE et al.			
Page 7 of 11		Filing Date: February 8, 2002			Examiner: TBA
		Group: 1626			
DCE	172	R. Horton, "Regulation of Lipid Transfer Between Lipoproteins By An Endogenous Plasma Protein: Selective Inhibition Among Lipoprotein Classes, Journal of Lipid Research, Vol. 35, 1994, pgs. 836-847			
	173	F. Nerdel et al., "Quartermay Salts of B-Amino Aldehydes and B-Iodoaldehydes", Chemische Berichte (Ed. H. Zahn), Vol. 98 (1965), pgs. 728-734			
	174	M. Newman et al., "The Conversion of Phenols to Thiophenols via Dialkylthiocarbamates", The Journal Of Organic Chemistry, Vol. 31, September-December 1966, pgs. 3980-3984			
	175	A. Orahovats et al., "A Ring Enlargement from Seven-to Ten-Membered-Ring Sulfonamide Derivatives", Helvetica Chimica Acta, Vol. 79, (1996), pgs. 1121-1128			
	176	H. Pan et al., "Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia", Clin. Pharmacol Ther. (1980) 9, 313, pgs. 201-207			
	177	N. Panagiotopoulos et al., "N(P-Bromophenyl) -4,5 - Dihydro -7, 8 - Dimethoxy Benzothiazepine - ONE 1, 1-Dioxide C17 H16 brNO5S", Cryst. Struct. Comm. (1980) 9, pgs. 313-319			
	178	R. Pasternak et al., "Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and "Normal" Cholesterol Levels", Annals of Internal Medicine, October 1, 1996, Vol. 125, Number 7, pgs. 529-538			
	179	R. Patra et al., "Conformational and Steric Requirements Of The Side Chain For Sulphur Participation In Benzthiepin Derivatives", Tetrahedron Letters, Vol. 30, No. 32, pgs. 4279-4282, 1989			
	180	R. Pierce et al., "Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy, JAMA, July 4, 1990, Vol. 264, No. 1, pgs. 71-75			
	181	W. Pirkle et al., "Trichlorosilane-Induced Cleavage. A Mild Method for Retrieving Carbinols From Carbamates", Journal Organic Chemistry, Vol. 42, No. 15, 1977, pgs. 2781-2782			
	182	W. Pirkle et al., "Dynamic NMR Studies of Disatereomeric Carbamates: Implications toward the Determination of Relative Configuration by NMR" Journal of Organic Chemistry, Vol. 44, No. 26, 1979, pgs. 4891-4896			
	183	W. Pirkle et al., "An Example of Automated Liquid Chromatography Synthesis of a Broad-Spectrum Resolving Agent and Resolution of 1-(Naphthyl) 2, 2, 2-Trifluoroethanol", The Journal of Organic Chemistry Volume 39, No. 26, 1974, pgs. 3904-3906			
	184	T. Pietzonka et al., "Phosphonate-Containing Analogs Of Cholesteryl Ester As Novel Inhibitors Of Cholesteryl Ester Transfer Protein", Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 16, pgs. 1951-1954, 1974.			
	185	Pravastatin Multicenter Study Group II, "Comparative Efficacy and Safety of Pravastatin and Cholestyramine Alone And Combined in Patients With Hypercholesterolemia", Archives of Internal Medicine, Vol. 153, June 14, 1993, pgs. 1321-1328			
	186	E. Reihner et al., "Regulation of Hepatic Cholesterol Metabolism In Humans: Stimulatory Effects of Cholestyramine on HMG-CoA Reductase Activity and Low Density Lipoprotein Receptor Expression In Gallstone Patients, Journal of Lipid Research, Volume 31, 1990, pgs. 2219-2226			
	187	R. Remick et al., "Comparison of Fluoxetine and Desipramine In Depressed Outpatients", Therapeutic Research, Vol. 53, No. 5, May 1993, pgs. 457-483			
	188	S. Rosenblum et al., "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 6, pgs. 973-980			

RECEIVED

MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION		U.S. Department of Commerce		Attorney Docket No. 161765.00467		TECH CENTER 1600/2900 10/068,297	
Page 8 of 11				Applicant(s): Len F. LEE et al.			
				Filing Date: February 8, 2002		Examiner: TBA Group: 1626	
DC	189	G. Salem et al., "Benzothiazine and Benzothizepine Derivatives: Structures of N-p-Bromophenyl-6, 7-Dimethoxy-1, 2-Benzothiazin-3(4H)-One 1, 1-Dioxide (BBTZ) and 4, 5-Dihydro-8,9-Dimethoxy-N-(5-Methyl-2-Pyridyl)-1,2-Benzothiazepin-3-One 1, 1-Dioxide (MPTE)", Acta Cryst. (1986) C42, pgs. 1581-1584					
	190	J. Sasaki et al., "Effects of Fluvastatin, A New Inhibitor of HMG-CoA Reductase, and Niceritol on Serum Lipids, Lipoproteins and Cholesterol Ester Transfer Activity In Primary Hypercholesterolemic Patients", International Journal of Clinical Pharmacology and Therapeutics, Vol. 33, No. 7, 1995, pgs. 420-426					
	191	K. Sindelar et al., "Neurotropic and Psychotropic Compounds. XXIX. Derivatives Of 2,3,4,5-Tetrahydro-1-Benzothiepin, Chemical Commun., Vol. 33, 1968, pgs. 4315-4327					
	192	K. Sindelar et al., "Benzocycloheptenes and Heterocyclic Analogues As Potential Drugs. III. Further Synthetic Experiments In The Series Of 1-Benzothiepin Derivatives, Vol. 37, 1972, 1195-1206					
	193	C. Sirtori, "New Targets For Lipid Lowering And Atherosclerosis Prevention", Pharmac. Ther. Vol. 67, No. 3., pgs. 433-447, 1995					
	194	Y. Son, "Purification and Characterization of Human Plasma Proteins That Inhibit Lipid Transfer Activities", Biochimica et Biophysica Acta, 795, 1984, pgs. 473-480					
	195	D. Sprecher et al., "Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients", Ann Intern Med. 1994; 120: pgs. 537-543					
	196	C.I. Stassinopoulou, et al., "C NMR Spectra of Benzothiazepinone, Benzothiazinone and Benzosulphonamide N-Substituted Derivatives" Department of Biology, Nuclear Research Center, 1994.					
	197	E. Stedronsky et al., "Interaction of Bile Acids and Cholesterol with Non-Systemic Agents Having Hypocholesterolemic Properties", Biochimica et Biophysica Acta., 1210, 1994, pgs. 255-287					
	198	I. Stein, et al., "Effects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia", Arch Intern Med. Vol. 150, February 1990, pgs. 341-345					
	199	E. Stein, et al., "Lovastatin Alone And In Combination For Treatment Of Primary Hypercholesterolemia", Alan R. Liss, Inc. 1988, pgs. 281-293					
200	K. Suckling, et al., "Cholesterol Lowering and Bile Acid Excretion in the Hamster with Cholestyramine Treatment, Atherosclerosis, 89, (1991) pgs. 183-190						
201	T. Swenson, "Mechanism of Cholesteryl Ester Transfer Protein Inhibition by a Neutralizing Monoclonal Antibody and Mapping of the Monoclonal Antibody Epitope", The Journal of Biological Chemistry, Vol. 264, No. 24, Aug. 25, pgs. 14318-14326, 1989						
202	A. Tall, "Plasma Cholesteryl Ester Transfer Protein", Journal of Lipid Research", Volume 34, 1993, pgs. 1255-1274						
203	Y. Tamura et al., "Novel Conversions of Benzo [b] thiophen-3 (2-H)-ones into 1, 2-Benzisothiazole and Tetrahydro-1, 2-Benzothiazepin-5-One Systems via Sulphimide Intermediates, J.C.S. Perkin I, pgs. 2830-2834, 1993						
204	K. Thurmond et al., "Water-Soluble Knedel-like Structures: The Preparation of Shell-Cross-Linked Small Particles", Journal American Chemistry Soc. Vol., 118, No. 30, 1996, pgs. 7239-7240						
205	P. Tyle, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, Vol. 3. No. 6 1986, pgs. 318-325						

RECEIVED
MAY 10 2002

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 161765.00467		TECH CENTER 1600/2990 10/068,297	
INFORMATION DISCLOSURE CITATION				Applicant(s): Len F. LEE et al.			
Page 9 of 11				Filing Date: February 8, 2002		Examiner: TBA Group: 1626	
	206	M. Une et al., "Metabolism of 3a, 7a-Dihydroxy-7b-Methyl-5b-Cholanoic Acid and 3a, 7B-Dihydroxy-7a-Methyl-5B-Cholanoic Acid Hamsters, Biochimica et Biophysica Acta, 833 (1985), pgs. 196-202					
	207	J. Vacek et al., "Comparison of Lavastatin (20 mg) and Nicotinic Acid (1.2g) With Either Drug Alone for Type II Hyperlipoproteinemia, The American Journal Of Cardiology, Vol. 76, July 15, 1995, pgs. 182-184					
	208	M. Van Heek et al., "In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey Through the Identification of the Active Metabolites of SCH48461", The Journal of Pharmacology and Experimental Therapeutics, Vol. 283, No. 1, pgs. 157-754, 1995.					
	209	G. Vega et al., "Treatment of Primary Moderate Hypercholesterolemia With Lovastatin (Mevinolin) and Colestipol", JAMA, Jan 2, 1987, Vol. 257, No. 1, pgs. 33-37					
	210	G. Wess et al., "Synthesis and Biological Activity of Bile Acid-Derived HMG-CoA Reductase Inhibitors. The Role of 21-Methyl in Recognition of HMG-CoA Reductase and the Ileal Bile Acid Transport System", Journal Of Medicinal Chemistry" 1994, 37, pgs. 3240-3246					
	211	J. Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels In WHHL Rabbits", Science Vol. 282, 10/23/98, pgs. 751-754, 1994.					
	212	O. Wiklund et al., "Pravastatin and Gemfibrozil Alone and in Combination for the Treatment of Hypercholesterolemia", The American Journal of Medicine Vol. 94, January 1993, pgs. 13-19					
	213	S. Wirebaugh et al., "A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin", Pharmacotherapy Vol. 12, Number 6, 1992, pgs. 445-450					
	214	J. Witztum, "Drugs Used In The Treatment of Hyperlipoproteinemias", The Pharmacological Basis of Therapeutics, 9 th Edition, pgs. 875-894, 1990.					
	215	Yan Xia et al., "Substituted 1,3,5-Triazines As Cholesterol Ester Transfer Protein Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 7, 1996, pgs. 919-922					
	216	A. Yamamoto et al., "Effects of Probucol on Xanthomata Regression in Familial Hypercholesterolemia", Am Journal Cardiolgy, 1986, 57: pgs. 29H-35H					
✓	217	K. Ytre-Arne et al., "Simvastatin and Cholestyramine In The Long-Term Treatment of Hypercholesterolaemia", Journal of Internal Medicine (1989): 226, pgs. 285-90					
EXAMINER <i>D. Lamberson</i>				DATE CONSIDERED <i>1/17/03</i>			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>**Copies of references not provided at the time of this submission.</p>							

→ +

RECEIVED

MAY 10 2002
P-TO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	10	of	11
-------	----	----	----

Complete if Known

Application Number	10/068,297
Filing Date	February 8, 2002
First Named Inventor	Len F. LEE et al.
Group Art Unit	1626
Examiner Name	TBA
Attorney Docket Number	161765.00467

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₈
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DLE ↓ ✓	222.	DE	3 122 489	A1				
	223.	EP	0 022 487	A1				
	224.	EP	0 033 538	B1				
	225.	EP	0 244 364	A2				
	226.	EP	0 409 201	A1				
	227.	GB	1 211 268					
	228.	GB	2 077 204	A				
	229.	WO	98/38182					
	230.	WO	98/40375					

Examiner
Signature

D. Lamberton

Date
Considered

1/17/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

RECEIVED

MAY 10 2002

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 065-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

11

of

11

Complete if Known

Application Number	10/068,297
Filing Date	February 8, 2002
First Named Inventor	Len F. LEE et al.
Group Art Unit	1626
Examiner Name	TBA
Attorney Docket Number	161765.00467

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	231.	Angelin, B., "Regulation of Hepatic Cholesterol Metabolism in Man," Ann. Med. 23, pp. 10-27 (1991).	
	232.	Blum, C. B., "Comparison of Properties of Four Inhibitors of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase," Am. J. Cardiol., 73(14), 3D-11D, (1994).	
	233.	Cayen, M.N., "Disposition, Metabolism and Pharmacokinetics of Anthyperlipidemic Agents in Laboratory Animals and Man," Pharmac. & Ther., 29, pp. 157-204 (1985).	
	234.	Da Col, et al., "Tolerability and Efficacy of Combination Therapy with Simvastatin Plus Gemfibrozil in Type II Refractory Familial Combined Hyperlipidemia," Curr. Therap. Research, Vol. 53, No. 5, pp. 473-483 (1993).	
	235.	Davignon, et al. "HMG CoA Reductase Inhibitors: A look back and a look ahead," Can. J. Cardiol., 8(8), pp. 843-864 (1992).	
	236.	Endo, A. "Chemistry, biochemistry and pharmacology of HMG-Co-A reductase inhibitors," Klin. Wochenschr. 66, pp. 421-427 (1988).	
	237.	Kramer et al., "Bile acid derived HMG-CoA reductase inhibitors," Biochimica et Biophysica Acta, 1227 pp. 137-154 (1994).	
	238.	Marcus, A., "Role of the HMG-CoA Reductase Inhibitors in the Treatment of Dyslipidemia: An Evolutionary Review," CVR&R, pp. 13-27 (January 1996).	

Examiner Signature	D. Landau	Date Considered	1/17/03
-----------------------	-----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.